The results reported here suggest that pharmacologic inhibition of p66 may also provide neuroprotection by the aforementioned mechanisms, and correspondingly, the results from the in vivo studies have demonstrated potential physiologic protection associated with p66 elimination in the context of EAE (Su et al., 2012), MS, and additional neurodegenerative conditions. The gene discussed is SHC1; the disease is myeloid sarcoma.